Author(s):
Kavitha Baburao, Naresh Kumar Panigrahi
Email(s):
npanigra@gitam.edu
DOI:
10.52711/0974-360X.2025.00538 
Address:
Kavitha Baburao1,2, Naresh Kumar Panigrahi1*
1Dept of Pharmaceutical Chemistry, GITAM School of Pharmacy, Vishakapatnam, India.
1,2Sarojini Naidu Vanita Pharmacy Maha Vidyalaya, Tarnaka, Hyderabad.
*Corresponding Author
Published In:
Volume - 18,
Issue - 8,
Year - 2025
ABSTRACT:
The emergence of methicillin and vancomycin resistant Staphylococcus aureus infections is a growing global health concern that is causing increasing illness and death. The growing problem of drug resistance has emphasized the need to discover and develop new antibacterial agents that work through different mechanisms to address this issue. To address this issue, a number of chalcone derivatives of Thiazolidine-2,4-dione were designed and synthesized as potential antibacterial agents. When evaluated against a panel of bacteria known as ESKAP, compounds 7a, 7h, and 7d were found to have highly selective inhibitory activity against Staphylococcus aureus at a concentration of 25µg/mL. This result suggests that these compounds have specific and powerful activity against S. aureus and have no effect against gram-negative bacteria.
Cite this article:
Kavitha Baburao, Naresh Kumar Panigrahi. Development of Potent Antibacterial Chalcone Derivatives Containing 2,4-Thiazolidinedione for Fighting Multidrug-Resistant Staphylococcus Aureus. Research Journal Pharmacy and Technology. 2025;18(8):3739-1. doi: 10.52711/0974-360X.2025.00538
Cite(Electronic):
Kavitha Baburao, Naresh Kumar Panigrahi. Development of Potent Antibacterial Chalcone Derivatives Containing 2,4-Thiazolidinedione for Fighting Multidrug-Resistant Staphylococcus Aureus. Research Journal Pharmacy and Technology. 2025;18(8):3739-1. doi: 10.52711/0974-360X.2025.00538 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2025-18-8-41
REFERENCES:
1. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. Pharm Ther. 2015; 40(4): 277-283.
2. Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century. Perspect Medicin Chem. 2014; 6: 25-64.
3. Rice LB. Mechanisms of resistance and clinical relevance of resistance to beta-lactams, glycopeptides, and fluoroquinolones. Mayo Clin Proc. 2012; 87(2):198-208.
4. Kumar A, Chashoo G, Rathore P et al. Thiazolidinones: A biologically active scaffold. Arab J Chem. 2017; 10: S2746-S2753.
5. Kumar D, Sharma PK, Singh R et al. Recent advances in biological activities of thiazolidinone derivatives: A review. Int J Pharm Sci Drug Res. 2011; 3(3): 147-154.
6. Sharma S, Rajak H and Mehta A. Thiazolidin-4-ones: a review on synthesis and biological activities. Pharm Lett. 2010; 2(3): 405-415.
7. Patel AV, Patel MM and Patel RG. Synthesis and biological evaluation of thiazolidinedione derivatives as antimicrobial agents. Research Journal of Pharmacy and Technology. 2022; 15(9), 4171-4176.
8. Abood NS and Al-Bayati RI. Synthesis and antimicrobial screening of new thiazolidine derivatives. Journal of Applied Pharmaceutical Science. 2019; 9(3): 109-114.
9. Ahmed OM, et al. Synthesis and evaluation of novel thiazolidin-4-one derivatives as antimicrobial agents targeting Gram-positive bacteria. Bioorganic Chemistry. 2020; 95: 103529.
10. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 2023; 33rd ed. CLSI supplement M100.